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A bs tr ac t
Background
Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment 
of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits 
continue after the progression to moderate-to-severe disease.
Methods
We assigned 295 community-dwelling patients who had been treated with donepezil 
for at least 3 months and who had moderate or severe Alzheimer’s disease (a score 
of 5 to 13 on the Standardized Mini–Mental State Examination [SMMSE, on which 
scores range from 0 to 30, with higher scores indicating better cognitive function]) 
to continue donepezil, discontinue donepezil, discontinue donepezil and start me-
mantine, or continue donepezil and start memantine. Patients received the study 
treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and 
on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 
0 to 60, with higher scores indicating greater impairment). The minimum clinically 
important differences were 1.4 points on the SMMSE and 3.5 points on the BADLS.
Results
Patients assigned to continue donepezil, as compared with those assigned to discon-
tinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points 
(95% confidence interval [CI], 1.3 to 2.5) and a score on the BADLS that was lower 
(indicating less impairment) by 3.0 points (95% CI, 1.8 to 4.3) (P<0.001 for both com-
parisons). Patients assigned to receive memantine, as compared with those assigned to 
receive memantine placebo, had a score on the SMMSE that was an average of 1.2 points 
higher (95% CI, 0.6 to 1.8; P<0.001) and a score on the BADLS that was 1.5 points 
lower (95% CI, 0.3 to 2.8; P = 0.02). The efficacy of donepezil and of memantine did not 
differ significantly in the presence or absence of the other. There were no significant 
benefits of the combination of donepezil and memantine over donepezil alone.
Conclusions
In patients with moderate or severe Alzheimer’s disease, continued treatment with 
donepezil was associated with cognitive benefits that exceeded the minimum clini-
cally important difference and with significant functional benefits over the course of 
12 months. (Funded by the U.K. Medical Research Council and the U.K. Alzheimer’s 
Society; Current Controlled Trials number, ISRCTN49545035.)
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF WARWICK LIBRARY on March 28, 2012. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 366;10 nejm.org march 8, 2012894
Most studies evaluating cholines-terase inhibitors for the treatment of Alzheimer’s disease have focused on 
patients with mild-to-moderate disease. Despite 
questions about the methods used in the trials1 and 
about the clinical significance of reported bene-
fits,1,2 guidelines advocate treatment with a cho-
linesterase inhibitor, although some recommend 
discontinuation when Alzheimer’s disease becomes 
severe.3 Evidence of the efficacy of memantine has 
been shown primarily in patients with moderate or 
severe Alzheimer’s disease.4 The findings of a study 
showing that combination therapy with meman-
tine and a cholinesterase inhibitor was more ef-
fective than treatment with a cholinesterase inhibi-
tor alone5 have not been replicated.6 Results from 
randomized, controlled trials involving patients 
with moderate-to-severe7,8 or severe9-12 Alzheimer’s 
disease suggest that cholinesterase inhibitors are 
associated with modest improvements in cognition 
and function, and these drugs are approved by the 
Food and Drug Administration in the United States 
for the treatment of severe Alzheimer’s disease. All 
the trials involving patients with severe Alzheimer’s 
disease, however, have involved nursing home resi-
dents, and none of the trials focusing on moderate-
to-severe or severe Alzheimer’s disease have inves-
tigated the strategy of continuing treatment with 
cholinesterase inhibitors in patients already taking 
those drugs. There is very limited evidence to guide 
the difficult decision regarding continuation or dis-
continuation of treatment when the disease pro-
gresses, but continued treatment is associated with 
an increase in adverse outcomes, including syncope, 
the need for insertion of permanent pacemakers, 
and hip fractures.13
We investigated whether community-living pa-
tients with Alzheimer’s disease, who have mod-
erate-to-severe disease and are already receiving 
donepezil, benefit from continuing treatment and 
whether initiating memantine at this point in the 
course of the disease is beneficial. We had three 
objectives: first, to test whether, over a period of 
52 weeks, continuation of donepezil, as compared 
with discontinuation of the drug, would be as-
sociated with better cognition and function; sec-
ond, to test whether memantine treatment, as 
compared with placebo memantine, would be as-
sociated with better cognition and function; and 
third, to test whether combining donepezil and 
memantine would provide additive or synergistic 
benefits.
Me thods
Study Design and Participants
The Donepezil and Memantine in Moderate to 
Severe Alzheimer’s Disease (DOMINO) study was a 
multicenter, double-blind, placebo-controlled, clin-
ical trial with a two-by-two factorial design. The 
outcomes were assessed for 52 weeks.14 We en-
rolled community residents who had caregivers 
who either lived with them or visited them at least 
daily. Eligible participants met standardized clini-
cal criteria15 for probable or possible moderate or 
severe Alzheimer’s disease, had been prescribed 
donepezil continuously for at least 3 months and 
had received a dose of 10 mg for at least the previ-
ous 6 weeks, and had a score between 5 and 13 on 
the Standardized Mini–Mental State Examination 
(SMMSE, on which scores range from 0 to 30, with 
higher scores indicating better cognitive func-
tion).16 In addition, each eligible patient’s prescrib-
ing clinician was considering a change in drug 
treatment (i.e., stopping donepezil or introducing 
memantine) on the basis of National Institute for 
Health and Clinical Excellence (NICE) guidelines3 
at the time, discussions with the patient and care-
givers, and the physician’s clinical judgment. Agree-
ment in writing to take part in the study was ob-
tained from the participants if they were considered 
to have the capacity to give informed consent, and 
the main caregivers gave written informed consent 
for their own involvement and assent for the pa-
tients’ involvement.
Patients were excluded if they had severe or 
unstable medical conditions, were receiving me-
mantine, or were considered to be unlikely to ad-
here to the study regimens. Details of the design 
have been published previously.14
Study Oversight
The study was overseen by King’s College London 
and was funded by the U.K. Medical Research 
Council (MRC) and the Alzheimer’s Society. Full 
ethical approval was received from the Scotland A 
Multicenter Research Ethics Committee. Pfizer-Eisai 
and Lundbeck donated supplies of the drugs and 
placebo but had no involvement in the design or con-
duct of the study or the analysis or reporting of the 
data. The study protocol, including the statistical 
analysis plan, is available with the full text of this 
article at NEJM.org. The first author vouches for the 
accuracy and completeness of the data and for the 
fidelity of the study to the protocol.
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Study Procedures
Participants were randomly assigned to one of four 
treatments: continuation of donepezil (at a dose 
of 10 mg per day, with placebo memantine, start-
ing in week 1); discontinuation of donepezil (ad-
ministration of donepezil at a dose of 5 mg during 
weeks 1 through 4 and placebo donepezil starting 
in week 5, plus placebo memantine starting in 
week 1); discontinuation of donepezil and initiation 
of treatment with memantine (administration of 
donepezil at a dose of 5 mg during weeks 1 through 
4, with placebo donepezil starting in week 5, and 
initiation of memantine at a dose of 5 mg in week 
1, with the dose increased in 5-mg increments 
weekly to a dose of 20 mg from week 4 on); or 
continuation of donepezil and initiation of me-
mantine (continuation of donepezil at a dose of 
10 mg and initiation of memantine at a dose of 
5 mg in week 1, with the dose increased in 5-mg 
increments weekly to a dose of 20 mg from week 
4 on). Treatment assignments were made (by tele-
phone) by the U.K. Medical Research Council Clini-
cal Trials Unit with the use of randomized mini-
mization17 (for full details, see the Supplementary 
Appendix, available at NEJM.org). The procedure 
involved stratifying groups according to center 
(among the 15 participating centers), duration of 
donepezil treatment before entry (3 to 6 months vs. 
>6 months), baseline SMMSE score (5 to 9, indi-
cating severe disease, vs. 10 to 13, indicating mod-
erate disease), and age (<60 years, 60 to 74 years, or 
≥75 years). In addition, to maintain concealment of 
the treatment assignments, the first 80 participants 
were assigned with the use of a prepared list of 
simple randomized assignments.17 Donepezil (in 
5-mg tablets), memantine (in 5-mg and 10-mg tab-
lets), and matched placebo tablets were provided by 
the manufacturers; patients, caregivers, clinicians, 
outcome assessors, and investigators were unaware 
of the treatment assignments. Efficacy and safety 
data were reviewed by an independent data moni-
toring and ethics committee every 6 months during 
the course of the trial.
Outcome Measures
The coprimary outcomes were scores on the 
SMMSE and on the caregiver-rated Bristol Activities 
of Daily Living Scale (BADLS, on which scores 
range from 0 to 60, with higher scores indicating 
greater impairment).18 Secondary outcomes were 
scores on the Neuropsychiatric Inventory19 (NPI, on 
which scores range from 0 to 144, with higher 
scores indicating increased behavioral and psycho-
logical symptoms), scores on the DEMQOL-Proxy20 
(on which scores range from 31 to 134, with high-
er scores indicating better patient health-related 
quality of life), and caregiver health status, as as-
sessed with the use of the General Health Ques-
tionnaire 1221 (GHQ-12, on which scores range 
from 0 to 12, with higher scores indicating in-
creased psychological symptoms in nonprofession-
al caregivers).
Statistical Analysis
A sample size of 800 was planned originally, but 
the size was adjusted to 430 on the basis of re-
duced standard deviations for the outcomes from 
a blinded analysis of accrued data. With a sample 
size of 430, we estimated that the study would have 
95% power to detect a 1.0-point difference between 
the donepezil and placebo groups or between the 
memantine and placebo groups in SMMSE scores 
and 90% power to detect a 2.0-point difference 
between the donepezil and placebo groups or be-
tween the memantine and placebo groups in 
BADLS scores at any one assessment point (ob-
jectives 1 and 2), assuming an expected rate of 
20% for missed visits, at a two-sided significance 
level of 5%. With this sample size, we estimated 
that the study would also have 96% power to de-
tect a 1.5-point difference in SMMSE scores and 
80% power to detect a 2.5-point difference in 
BADLS scores between the combination-therapy 
and monotherapy groups at any one assessment 
point (objective 3).
Unless otherwise specified, we performed the 
analyses on data from all patients who underwent 
randomization and who received at least one dose 
of study drug, applying the principle of intention to 
treat as much as was practically possible, given any 
missing data. Data from participants were ana-
lyzed according to the groups to which they had 
been assigned, irrespective of withdrawal from the 
assigned study drug or initiation of open-label 
treatment. An analysis of variance was used to 
identify significant differences in continuous base-
line characteristics across the four study groups, 
and Fisher’s exact test was used to identify differ-
ences in categorical baseline characteristics.
The primary analyses of the primary outcomes 
and the continuous secondary outcomes were 
conducted with the use of multilevel modeling 
repeated-measures regression,22 adjusted for base-
line scores and for the four minimization factors 
The New England Journal of Medicine 
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(center, duration of donepezil treatment before 
entry, baseline SMMSE score, and age). All avail-
able scores at every visit, regardless of whether the 
patient was still taking the trial medication or had 
switched to open-label treatment, were included in 
the primary analysis, and there was no imputation 
of missing scores. The scheduled, rather than the 
actual, visit week was used in the model. For each 
outcome, two models were fitted — one with the 
interaction of donepezil with memantine, to esti-
mate the additional benefit of combination therapy 
(objective 3) and to test for the interaction, and one 
without the interaction, to estimate the difference 
between the active drug (donepezil or memantine) 
and placebo (objectives 1 and 2). Different random-
effects structures were compared with the use of 
Akaike’s information criterion.23 The chosen mod-
el included random effects for each visit with an 
unstructured covariance matrix; full details are 
provided in the Supplementary Appendix.
The length of time that participants in the four 
groups took the study drugs was compared with 
the use of the log-rank test for equality of survivor 
functions and a Cox proportional-hazards model 
to quantify differences among the groups. The 
incidence of serious adverse events was compared 
among the groups by means of Poisson regression. 
Sensitivity analyses were performed to determine 
the effect of missing data and of discontinuation 
of treatment; details are provided in the Supple-
mentary Appendix. The analyses were conducted 
with the use of Stata software, version 11.2.24 
Since the primary objectives were well defined and 
ordered, adjustment for multiple testing was not 
indicated in the analysis.25 For secondary out-
come measures and outcomes at assessment points 
other than those during the 52-week study-treat-
ment period, we defined statistical significance at 
the 99% confidence interval level to compensate 
for multiple comparisons.
Before commencing the data analysis, we pub-
lished values for minimum clinically important 
differences for the SMMSE (1.4 points), the BADLS 
(3.5 points), and the NPI (8 points); these values 
were based on 0.4 SD of the change from baseline 
in the first 127 participants who completed the 
DOMINO trial.26
R esult s
Participants
During the period from February 2008 to March 
2010, a total of 295 participants were enrolled. 
Recruitment was slower than anticipated, and it 
was not possible to extend the recruitment period, 
since the public funder of the study (MRC) believed 
that the disadvantages of a delay in reporting re-
sults outweighed the benefits of increasing the 
power of the study. The baseline characteristics of 
the participants in the four treatment groups were 
broadly similar (Table 1). Figure 1 shows the num-
bers of patients who were enrolled, were assigned 
to a study group, and completed follow-up. Figure 2 
shows the number of participants in each group 
who were still receiving the study drug at each 
study visit and the cumulative probability of dis-
continuation of the study drug. The probability of 
withdrawal from the study drug among patients 
assigned to continue donepezil was half that among 
patients assigned to discontinue donepezil (hazard 
ratio for withdrawal among patients assigned to 
continued donepezil treatment, 0.51; 95% confi-
dence interval [CI], 0.36 to 0.72; P<0.001). Patients 
assigned to memantine also had a lower proba-
bility of treatment withdrawal than did those as-
signed to placebo memantine (hazard ratio, 0.66; 
95% CI, 0.47 to 0.93; P = 0.02).
Primary Outcome Measures
The mean scores on the SMMSE and the BADLS 
in all study groups and at all visits are shown in 
Figure 3. The between-group differences in primary 
outcome measures at all trial visits are shown in 
Table 2. Patients who were assigned to continue 
taking donepezil, as compared with those assigned 
to discontinue donepezil, had scores on the SMMSE 
that were higher (indicating better cognitive func-
tion) by an average of 1.9 points (95% CI, 1.3 to 
2.5; P<0.001) and scores on the BADLS that were 
lower (indicating less functional impairment) by an 
average of 3.0 points (95% CI, 1.8 to 4.3; P<0.001). 
For both these outcomes, there was significant het-
erogeneity in treatment efficacy over time (P = 0.002 
and P = 0.004, respectively), with less benefit ap-
parent at the 6-week assessment than at later time 
points. From 6 weeks onward, the differences be-
tween the treatment groups were roughly parallel, 
and we therefore report average effects.
Patients who were assigned to receive me-
mantine, as compared with those who were as-
signed to receive placebo memantine, had scores 
on the SMMSE that were higher by an average of 
1.2 points (95% CI, 0.6 to 1.8; P<0.001) and 
scores on the BADLS that were lower by an aver-
age of 1.5 points (95% CI, 0.3 to 2.8; P = 0.02); both 
these values were smaller than the minimum 
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clinically important difference. This reflects the 
average effect among patients assigned to continue 
donepezil as well as among those assigned to dis-
continue donepezil. The interactions of meman-
tine therapy with visit were not significant. For 
both donepezil and memantine, the benefits with 
respect to scores on the SMMSE and the BADLS 
appeared to be larger in the absence of the other 
agent than in the presence of the other agent (Ta-
ble S4 in the Supplementary Appendix), but these 
differences were not significant (P = 0.14 and 
P = 0.09, respectively, for the tests for interac-
Table 1. Baseline Characteristics of the Participants, According to Treatment Group.*
Characteristic Donepezil Tapered and Discontinued Donepezil Continued Total (N = 295)
Placebo Memantine 
Added (N = 73)
Active Memantine 
Added (N = 76)
Placebo Memantine 
Added (N = 73)
Active Memantine 
Added (N = 73)
Age — yr 77.7±8.0 76.2±8.9 77.2±7.5 77.5±9.0 77.1±8.4
Sex — no. (%)
Male 26 (36) 30 (39) 22 (30) 24 (33) 102 (35)
Female 47 (64) 46 (61) 51 (70) 49 (67) 193 (65)
Race — no. (%)†
White 71 (97) 73 (96) 69 (95) 67 (92) 280 (95)
Black 2 (3) 2 (3) 1 (1) 4 (5) 9 (3)
Other 0 1 (1) 3 (4) 2 (3) 6 (2)
Previous duration of donepezil therapy 
— no. (%)
3 to <6 mo 3 (4) 4 (5) 3 (4) 4 (5) 14 (5)
6 to <12 mo 8 (11) 4 (5) 9 (12) 3 (4) 24 (8)
12 to <24 mo 15 (21) 17 (22) 14 (19) 16 (22) 62 (21)
24 to <36 mo 19 (26) 17 (22) 18 (25) 8 (11) 62 (21)
36 to <60 mo 19 (26) 20 (26) 21 (29) 31 (42) 91 (31)
≥60 mo 9 (12) 14 (18) 8 (11) 11 (15) 42 (14)
SMMSE score‡
Mean 9.1±2.4 9.2±2.5 9.0±2.8 9.1±2.6 9.1±2.6
Distribution — no. (%)
5–9, indicating severe 
Alzheimer’s disease
39 (53) 39 (51) 38 (52) 38 (52) 154 (52)
10–13, indicating moderate 
Alzheimer’s disease
34 (47) 37 (49) 35 (48) 35 (48) 141 (48)
BADLS score§ 28.6±8.9 27.1±9.0 28.2±9.0 26.9±9.8 27.7±9.2
NPI score¶ 22.9±17.0 23.1±16.2 22.3±16.7 20.3±14.4 22.2±16.1
DEMQOL-Proxy score‖ 101.4±11.7 96.5±15.3 98.3±13.5 100.9±12.9 99.3±13.5
GHQ-12 score** 2.8±3.1 3.1±3.1 2.3±2.3 1.8±2.3 2.5±2.8
* Plus–minus values are means ±SD. Apart from two missing General Health Questionnaire 12 (GHQ-12) scores (one for a caregiver of a 
patient who discontinued donepezil and received placebo memantine and one for a caregiver of a patient who discontinued donepezil and 
received active memantine), scores were available for all 295 enrolled patients at baseline. There were no significant differences among 
the groups for any of the baseline characteristics, with the exception of the total GHQ-12 score (P = 0.03).
† Race was determined by the investigator.
‡ Scores on the Standardized Mini–Mental State Examination (SMMSE) range from 0 to 30, with higher scores indicating better cognitive 
function. Because of eligibility criteria, the scores for patients in this trial were between 5 and 13.
§ Scores on the Bristol Activities of Daily Living Scale (BADLS) range from 0 to 60, with higher scores indicating greater functional impairment.
¶ Scores on the Neuropsychiatric Inventory (NPI) range from 0 to 144, with higher scores indicating increased behavioral and psychological 
symptoms.
‖ Scores on the DEMQOL-Proxy range from 31 to 134, with higher scores indicating better patient health-related quality of life.
** Scores on the GHQ-12, which measures caregiver health status, range from 0 to 12, with higher scores indicating increased psychological 
symptoms in informal caregivers.
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tion). There was no significant benefit of adding 
memantine to donepezil, with respect to scores on 
the SMMSE (0.8 points higher with memantine 
than with placebo; 95% CI, −0.1 to 1.6; P = 0.07) or 
with respect to scores on the BADLS (0.5 points 
lower with memantine than with placebo; 95% CI, 
−2.2 to 1.2; P = 0.57).
The severity of dementia at entry significantly 
influenced the effect of donepezil on SMMSE 
scores, with larger benefits observed in patients 
with moderate disease (SMMSE score, 10 to 13) 
than in those with severe disease (SMMSE score, 
5 to 9). The average difference in scores between 
the groups assigned to continue donepezil and the 
groups assigned to discontinue donepezil was 
2.6 points (95% CI, 1.5 to 3.7) among patients 
with moderate disease (P<0.001) and 1.3 points 
(95% CI, 0.2 to 2.4) among patients with severe 
disease (P = 0.02). Because we undertook several 
tests for interaction, this difference according to 
the severity of dementia, which was only moder-
ately significant, may have arisen by chance and 
needs to be confirmed, particularly since the se-
verity of dementia did not have a significant effect 
on the difference in the BADLS score that was 
observed with continued, as compared with dis-
295 Entered study and underwent randomization
318 Patients were assessed for eligibility
23 Were excluded
2 Declined to participate
21 Did not meet inclusion criteria
19 Had inadmissible SMMSE score
1 Did not have diagnosis of Alzheimer’s disease
1 Did not maintain 10 mg donepezil for 6 wk
73 Were assigned to have
donepezil continued and
active memantine added
73 Were assigned to have
donepezil continued and
placebo memantine added
76 Were assigned to have
 donepezil discontinued and
active memantine added
73 Were assigned to have
 donepezil discontinued and
placebo memantine added
72 Were included in primary
intention-to-treat analysis
1 Did not start treatment
and was excluded
74 Were included in primary
intention-to-treat analysis
2 Did not start treatment
and were excluded
73 Were included in primary
intention-to-treat analysis
72 Were included in primary
intention-to-treat analysis
1 Did not start treatment
and was excluded
55 Completed follow-up
9 Died
8 Withdrew
1 Was lost to follow-up
51 Completed follow-up
10 Died
15 Withdrew
54 Completed follow-up
13 Died
6 Withdrew
58 Completed follow-up
7 Died
8 Withdrew
29 Were included in per-
protocol analysis
43 Were excluded owing
to <70% treatment
adherence
42 Were included in per-
protocol analysis
32 Were excluded
31 Had <70% treat-
ment adherence
1 Took open-label
donepezil or meman-
tine during trial
50 Were included in per-
protocol analysis
23 Were excluded
21 Had <70% treat-
ment adherence
2 Were erroneously
enrolled
51 Were included in per-
protocol analysis
21 Were excluded
19 Had <70% treat-
ment adherence
1 Took open-label
donepezil or meman-
tine during trial
1 Was erroneously
enrolled
Figure 1. Enrollment, Randomization, and Follow-up.
SMMSE denotes Standardized Mini–Mental State Examination.
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continued, donepezil therapy or on the differences 
in SMMSE or BADLS scores observed with meman-
tine therapy, as compared with placebo.
Secondary Outcome Measures
Patients who received memantine, as compared 
with those who received placebo memantine, had 
scores on the NPI that were lower (indicating few-
er behavioral and psychological symptoms) by an 
average of 4.0 points (99% CI, 0.6 to 7.4; P = 0.002), 
representing a smaller benefit than the minimum 
clinically important difference. We did not observe 
a significant difference in scores on the NPI with 
the continuation, as compared with the discon-
tinuation, of donepezil therapy (2.3 points lower 
with continuation; 95% CI, −1.1 to 5.7; P = 0.08). 
The addition of memantine to donepezil, as com-
pared with the addition of placebo memantine to 
donepezil, resulted in a decrease in the NPI score 
that was greater by 5.1 points (99% CI, 0.3 to 9.8; 
P = 0.006). In contrast with results on the SMMSE 
and BADLS, for both donepezil and memantine, 
the benefits with respect to the NPI score ap-
peared to be larger in the presence of the other 
agent than in the absence of the other agent (Ta-
ble S4 in the Supplementary Appendix), but these 
differences were not significant (P = 0.42). Both 
continuation of donepezil therapy, as compared 
with discontinuation, and memantine therapy, as 
compared with placebo, resulted in larger average 
decreases (indicating fewer psychological symp-
toms) across trial visits in GHQ-12 scores for care-
giver health status (a 0.5-point larger decrease with 
continuation vs. discontinuation of donepezil; 99% 
CI, −0.01 to 1.0; P = 0.01; and a 0.5-point larger 
decrease with memantine vs. placebo; 95% CI, 
−0.1 to 0.9; P = 0.03); however, the differences did 
not reach significance, which was defined at P<0.01 
to allow for multiple secondary outcome measures.
Sensitivity Analyses
Patients who withdrew from treatment after the 
18-week visit or after the 30-week visit had a low-
er score on the SMMSE and a higher score on the 
BADLS at their last visit before withdrawal than 
did those who continued treatment (Table S3 in 
the Supplementary Appendix). Patients who with-
drew at any point during the study had lower 
SMMSE scores and higher BADLS scores after with-
drawal than did those who continued to receive 
treatment. Of the 137 patients who withdrew from 
treatment before the end of the trial, 64 (47%) at-
tended the 52-week visit (with 1 patient missing 
the SMMSE assessment). A number of sensitivity 
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Figure 2. Kaplan–Meier Actuarial Plot of the Cumulative Probability of Withdrawal from the Assigned Study Drug.
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sponding to the usual visit dates).
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analyses were conducted to assess the effect of 
treatment withdrawal and missing outcome as-
sessments on the results. The results of the sen-
sitivity analyses were broadly similar to those of 
the primary analysis (see Table S3 in the Supple-
mentary Appendix).
Safety
A total of 188 serious adverse events were reported, 
of which 6 (2 in the group receiving placebo done-
pezil and placebo memantine, 2 in the group re-
ceiving memantine and placebo donepezil, and 2 in 
the group receiving donepezil and memantine) 
were considered to be possibly related to the study 
drugs. None were considered to be unexpected se-
rious adverse reactions. There was no evidence that 
the incidence of serious adverse events or death 
differed according to treatment group (P = 0.77). 
Details of the serious adverse events and deaths in 
all treatment groups are provided in Table S5 in the 
Supplementary Appendix.
Discussion
This double-blind, placebo-controlled trial involv-
ing community-living patients with moderate or 
severe Alzheimer’s disease who were already re-
ceiving treatment with a cholinesterase inhibitor 
showed that there were modest cognitive and func-
tional benefits of continuing donepezil over the 
course of 12 months. The difference in scores on 
the SMMSE between those who continued donep-
ezil and those who discontinued it exceeded the 
prespecified minimum clinically important differ-
ence of 1.4 points, but the difference in scores on 
the BADLS was less than the minimum clinically 
important difference of 3.5 points. The initiation of 
memantine therapy was also associated with sig-
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nificantly better cognition and function, although 
the magnitude of the benefit was smaller than it 
was with donepezil and the differences between 
patients who received memantine and those who 
received placebo were smaller than the predefined 
minimum clinically important difference. Meman-
tine, as compared with placebo, was associated 
with the emergence of fewer behavioral symptoms 
as measured by the NPI, but the difference did not 
reach the minimum clinically important difference. 
Combined treatment with donepezil and meman-
tine was not significantly superior to treatment 
with donepezil alone with respect to any of the pri-
mary or secondary outcomes.
The improvements in cognition and function 
associated with donepezil and memantine were 
small relative to the overall size of the decline in 
cognitive and functional status that was seen in 
all patients. Although the cognitive benefit as-
sociated with donepezil therapy exceeded a dis-
tribution-based minimum clinically important dif-
ference,26,27 the cognitive benefits associated with 
memantine treatment were smaller and did not 
reach the minimum clinically important differ-
ence. The cognitive benefit associated with con-
tinuing donepezil was equivalent to 32%, and that 
associated with starting memantine was equiva-
lent to 20%, of the total deterioration (a decrease of 
5.8 SMMSE points) over the course of 12 months28,29 
that was seen in the group discontinuing donepezil 
and receiving placebo memantine. The functional 
benefits of continuing donepezil were equivalent to 
23%, and those of starting memantine were 
equivalent to 11%, of the deterioration (an increase 
of 12.8 BADLS points) seen over the course of 
12 months in the group discontinuing donepezil 
and receiving placebo memantine (Fig. 3). Meman-
tine treatment was associated with a significantly 
smaller worsening of NPI scores, an observation 
that is consistent with the findings in another 
study,30 with a benefit that was equivalent to 83% 
of the 12-month deterioration (4.8 NPI points) seen 
in the group discontinuing donepezil and receiving 
placebo memantine.
In this study, patients who discontinued donep-
ezil did not have abrupt withdrawal phenome-
na,31 but withdrawal from the study drug was 
significantly more common among participants 
assigned to discontinue donepezil and receive pla-
cebo donepezil than among those assigned to 
continue donepezil, with the majority of withdraw-
als occurring between week 6 and week 18 (Fig. 2). 
Modest reductions in caregivers’ psychological 
symptoms that were seen with donepezil or me-
mantine did not reach statistical significance but, 
considered together with lower rates of withdraw-
al, suggest the possibility that caregivers who live 
with patients perceived treatment benefits.
Participants were recruited from National 
Health Service clinics across England and Scotland 
and were representative of patients with Alzhei-
mer’s disease who were treated with cholinesterase 
inhibitors. Despite difficulties with recruitment, 
we detected significant benefits of continued do-
nepezil therapy with respect to cognitive and 
functional outcomes (P<0.001), which was the 
first objective of our study. With respect to our 
second objective, the benefits of starting meman-
tine were smaller than the benefits of continuing 
donepezil, but they were significant at the P<0.05 
level. With respect to our third objective, determin-
ing whether the combination of donepezil and 
memantine treatment showed additive benefits, 
we did not find significant heterogeneity in the 
efficacy of donepezil or memantine in the pres-
ence or absence of the other drug. Subgroup 
analyses, however, failed to show significant ben-
efits of adding memantine to donepezil treatment.
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